Article
|
By Craig Parker, Surrozen,
Lonza
Surrozen’s President & CEO, Craig Parker, discusses how the expertise, resources and flexibility of Lonza have been fundamental in advancing its novel and complex bispecific antibody candidates that target the WNT pathway.
|